Primer: YishengBio (1872307D HK) - Aug 2026
Primary Revenue Driver Faces Market Headwinds: The company, now named LakeShore Biopharma, is heavily reliant on its sole commercial product,...
93 Views
Pre-IPO YishengBio Co., Ltd - Here Are the Concerns Despite Solid Market Potential
This article mainly analyzed YishengBio in terms of market potential, competitive landscape, financial position, and concerns (insurance coverage,...
556 Views
YishengBio (依生生物) Pre-IPO: Need a Faithful Bet in PIKA
YishengBio is a China-based biopharmaceutical company with a focus of developing PIKA based technology for vaccine and oncology. We like the...
497 Views
No more insights